These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 20524793)

  • 21. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.
    Sharifi N
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1046-51. PubMed ID: 19719456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abiraterone acetate for the treatment of prostate cancer.
    Ryan CJ; Cheng ML
    Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer.
    Fletterick RJ
    BJU Int; 2005 Dec; 96 Suppl 2():2-9. PubMed ID: 16359432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Castration-resistant prostate cancer: adaptive responses in the androgen axis.
    Egan A; Dong Y; Zhang H; Qi Y; Balk SP; Sartor O
    Cancer Treat Rev; 2014 Apr; 40(3):426-33. PubMed ID: 24139549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.